The latest: Koolearn Technology Holding Ltd. (1797.HK) said it will stop offering after-school tutoring services for kindergartners to ninth-year students (K-9) for academic subjects included in China’s compulsory education system. The Hong Kong-listed online arm of education giant New Oriental (EDU.US) said the cessation will take place by the end of November, according to a statement released after markets closed on Monday.

Looking Up: The move, a response to China’s ban on such classes by for-profit companies, will remove a huge overhang for Koolearn, allowing the education services provider to move forward on a more solid footing. China’s after-school tutoring services sector has been in a state of turmoil since new rules recently took effect aimed at easing pressure on students from after-school coursework.

Take Note: Classes being discontinued accounted for between 58% and 73% of the company’s K-12 education services business over the company’s last two fiscal years through May 2021, Koolearn estimated. K-12 services generated 787 million yuan ($123 million), or more than half of Koolearn’s total revenue of 1.4 billion yuan in its latest fiscal year.

Digging Deeper: The roughly dozen publicly-listed Chinese companies offering after-school tutoring services have lost most of their value since the start of the year, with some stocks down 90% or more. Koolearn is one of the first companies to announce how it will move ahead under the new restrictions. Based on its latest announcement, the discontinued business should result in a reduction of 32% to 40% of its current revenues.

Market Reaction: Koolearn shares were down 2.8% at HK$4.88 late on Tuesday, giving the company a market value of HK$4.9 million ($630 million). The shares are down about 80% this year, but have stabilized at their current level since early August as more details of the new restrictions emerged.

To subscribe to Bamboo Works free weekly newsletter, click here   

Recent Articles

Founded in 2008, RemeGen develops and sells novel drugs in the areas of autoimmunity, oncology, ophthalmology and other major diseases.

FAST NEWS: RemeGen scales back A-share fundraising plan

The Latest: Novel drug maker RemeGen Co. Ltd. (9995.HK; 688331.SH) announced Wednesday that it has reduced its fundraising target through a planned issue of new A-shares from a previous 2.55 billion yuan ($350…
Favorable policies have helped China’s property market to record two consecutive months of improvement.

Has China’s real estate market turned a corner?

Favorable policies have helped China’s property market to record two consecutive months of improvement   By CCB International The latest figures from China’s National Bureau of Statistics point to significant…